Find Funding Opportunities

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required or Clinical Trial Optional FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

Notice Special Interest: Administrative Supplements NIH grants Add Expand Research Focused Maternal Mortality Notice Number: NOT-OD-20-104 Key Dates Release Date: 05, 2020 First Available Due Date: 05, 2020 Expiration Date: June 23, 2020 Related Announcements PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued Office The Director, National Institutes Health OD) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Library Medicine NLM) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) National Institute Alcohol Abuse Alcoholism NIAAA) - New participating organization of 05/08/2020 due dates on/after 05/08/2020 applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Division Program Coordination, Planning Strategic Initiatives, Office Disease Prevention ODP) Office Behavioral Social Sciences Research OBSSR) Office Research Women's Health ORWH) Purpose Office the Director the National Institutes Health NIH) announces opportunity investigators relevant active NIH-supported grants the participating Institutes listed above address scientific priorities will lay foundation the Implementing Maternal health PRegnancy Outcomes Vision Everyone IMPROVE), is development. estimated 700 women die year the U.S. conditions related or associated pregnancy childbirth highest rate among developed nations), over 50,000 women experience severe maternal morbidity SMM). response the rising maternal mortality MM) the United States U.S.), IMPROVE initiative support research how mitigate preventable MM, decrease SMM, promote health equity the U.S. IMPROVE aim use integrated approach understand biological, behavioral, sociocultural, structural factors contributing MM/SMM building evidence base improved care outcomes specific populations regions the country. IMPROVE be multipronged, innovative research initiative designed target health disparities populations disproportionately affected MM/SMM, including African American AA), American Indian/Alaskan Native AI/AN), Asian Pacific Islander, Hispanic/Latina, very young women women advanced maternal age, people disabilities. Geographical disparities social determinants health SDoH), including education, racism, socioeconomic standing also addressed the IMPROVE approach. Causes SMM MM multifaceted. the U.S., leading causes cardiovascular disease, hemorrhage, infection. Significant contributing factors include comorbid conditions e.g., diabetes, obesity, mental health issues, substance disorders) structural health care system factors. Therefore, is necessary implement comprehensive strategies address preventable contributors SMM/MM disproportionately affected populations. order rapidly improve our understanding the leading causes pregnancy-related pregnancy-associated morbidity, including SMM, MM during pregnancy, delivery, up one year post-partum to expand research development risk stratification approaches mitigation strategies, NIH soliciting submission applications Administrative Supplements active social, biobehavioral, fundamental science awards. Applicants encouraged incorporate where appropriate community partnerships focus disparities race ethnicity, age, disability status, geographic region within overarching research areas. Projects involve secondary analysis existing data collection new data. Applicants responding this NOSI strongly encouraged describe plans rapid sharing data results well innovative data analytics approaches Goal 3, NIH Strategic Plan Data Science). Applications response this NOSI should aligned one more these equally significant goal Goal 1: Incorporate community partnerships participation domestic MM pregnancy-related pregnancy-associated morbidity research resolve health disparities attain equity maternal health. Goal 2: Expand research the leading causes MM pregnancy-related pregnancy-associated morbidity the U.S. strengthen evidence-based care prevention strategies improve outcomes. Goal 3: Develop integrated understanding pregnancy-related pregnancy-associated morbidity MM causes, including underlying comorbidities, mechanisms identify preventable risk factors develop early effective interventions. Areas research interests include are limited the following: Identify determinants risk protection detect most vulnerable populations provide points intervention cardiovascular, stroke, abnormal placentation, hemorrhage, gestational diabetes, infection immunity, mental health, substance abuse research areas. Determine factors related race, ethnicity, age affect underlying leading causes, contributors, mechanisms MM/pregnancy-related pregnancy-associated morbidity. Identify multi-level individual, interpersonal, community, sociocultural) determinants maternal health disparities, well factors contribute optimal maternal outcomes high risk communities. omics” other novel technologies existing well-characterized cohorts in clinical trials pregnant women accelerate identification diagnostic, predictive, therapeutic biomarkers including brain structure function alterations) pregnancy-related adverse maternal health outcomes. Determine contribution immune system dysregulation autoimmunity during pregnancy the postpartum period leading poor pregnancy maternal health outcomes. Identify predictors contribution maternal mortality postpartum anxiety depression harmful substance and drug overdoses, including relevant environmental social factors e.g., institutional racism, access care, intimate partner violence, etc.) affect them. Develop and/or test interventions addressing stress, perinatal postpartum depression harmful substance e.g., peer support, complementary health approaches, strategies coordinate integrate OB/GYN mental health substance treatment services) assess impact maternal health outcomes. Develop approaches interventions target pregnancy-related cardiovascular disease and/or underlying cardiovascular risk factors during perinatal postnatal periods assess impact maternal health status. Identify barriers opportunities design strategies implementing clinical guidelines blood pressure management, physical activity, diet tailored high risk communities. Link establish feasibility linking existing MM/pregnancy-related pregnancy-associated morbidity datasets, electronic health records, clinical biomarker data existing national cohorts, biobank data, national surveys registries. Develop tools modify existing tools e.g. Smartwatch ECG, blood pressure, sleep monitor heart rate monitor, devices measure real-time stress level, wearable devices detect postpartum depression, predictive modeling tools, etc.) recognize pregnancy related warning signs. Identify, monitor, target pregnancy-related pregnancy-associated morbidity/MM-related ischemic stroke arterial venous), intra-cerebral hemorrhage, epilepsy, migraine, nervous system infections, headache, encephalopathy syndromes, cognitive impairment. Develop strategies enhancing community partnerships engages women their families, community healthcare providers systems, local governments identify barriers and community-specific opportunities optimal maternal health equity. Design test strategies improve interdisciplinary coordinated care, particularly during transition periods, prenatal one year postpartum prevent mortality adverse health outcomes. Applications incorporate community partnerships interdisciplinary research strongly encouraged. administrative supplements extend work awarded the parent grant, proposal needs be within scope the project is already supported. Supplements awards clinical trials allowed. Supplement applicants must demonstrate the additional NIH funding advance science and/or medicine above current funding level. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent: PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional instructions the SF424 R&R) Application Guide and PA-18-591 (or reissue) must followed, the following additions: Application Due Date(s) – June 22, 2020 5:00 PM local time applicant organization. funding consideration, applicants must include NOT-OD-20-104” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. project budget periods must within currently approved project period the existing parent award. Individual requests be more 150,000 direct costs the entire project period. project period be limited 1 year. Research Strategy section the application limited 6 pages should include following information Discussion the scientific rationale relevance maternal mortality. Administrative supplement applications PA-18-591 must the application form package the Competition ID contains FORMS-E-ADMINSUPP”. FOA be reissued application form packages containing FORMS-F-ADMINSUPP” May 25, 2020. Submissions the reissued FOA be accepted or after 25, 2020 through expiration date this Notice. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify program contact the Institute supporting parent award a request been submitted response this FOA order facilitate efficient processing the request Review Process IC conduct administrative reviews applications will be prioritized NIH staff the Maternal Mortality Task Force. Criteria: Priority be given projects incorporate community needs perspectives that focus a population disproportionately affected MM/SMM. NIH staff review following: Does work proposed address or of goals defined earlier this notice NOT-OD-20-104)? the project designed advance our understanding the mechanisms, interventions, risk profiles pregnancy-related pregnancy-associated morbidity/MM the U.S.? Does supplement propose address or of leading preventable causes pregnancy-related pregnancy-associated morbidity/MM the U.S. outlined this notice NOT-OD-20-104)? not, there strong justification addressing preventable causes? the proposal address pregnancy-related pregnancy-associated morbidity/MM one more high risk populations based race/ethnicity, age, geographic region? the work proposed within scope the active parent award? the parent award progressing satisfactorily/according planned timeline milestones? the proposed project technically feasible within supplement budget funding period? the overall strategy, methodology, analyses proposed the supplement application well-reasoned appropriate accomplish activities the proposed project period?   Inquiries Please direct inquiries to: Nahida Chakhtoura Eunice Kennedy Shriver National Institute Child Health Human Development NICHD)National Institute Child Health Human Development Telephone: 301-435-6872 Email:  nahida.chakhtoura@nih.gov Soju Chang National Center Advancing Translational Sciences NCATS) Telephone: 301-827-9206 Email: soju.chang@nih.gov Della White National Center Complementary Integrative Health Telephone: 301-827-6358 Email: whitede@mail.nih.gov Lisa Neuhold National Eye Institute Telephone: 301-451-2020 Email: lneuhold@nei.nih.gov Jyoti Dayal National Human Genome Research Institute Telephone: 301-480-2307 Email: jyotig@mail.nih.gov NHLBI IMPROVE Initiative National Heart, Lung, Blood InstituteEmail: NHLBI_IMPROVEinitiative@nhlbi.nih.gov Rosaly Correa-de-Araujo National Institute Aging Telephone: 301-496-6762 Email: rosaly.correa-de-araujo@nih.gov Juliane Caviston National Institute Allergy Infectious Diseases Telephone: 301-761-5094 Email: juliane.caviston@nih.gov Marisol Espinoza-Pintucci National Institute Arthritis Musculoskeletal Skin Diseases Telephone: 301-827-6959 Email: marisol.espinoza-pintucci@nih.gov Minki Chatterji National Institute Drug Abuse Telephone: 301-827-5435 Email: minki.chatterji@nih.gov Trinh T. Ly National Institute Deafness Other Communication Disorders Telephone: 301-435-4085 Email: trinh.ly@nih.gov Christine Maric-Bilkan National Institute Diabetes Digestive Kidney Diseases Telephone: 301-435-0486 Email: christine.maric-bilkan@nih.gov Zuzana Justinova National Institute General Medical Sciences Email: zuzana.justinova@nih.gov Lauren D. Hill National Institute Mental Health Telephone: 301-443-2638 Email: hillla@mail.nih.gov Jennifer Alvidrez National Institute Minority Health Health Disparities Telephone: 301-594-9567 Email: jennifer.alvidrez@nih.gov Adam Hartman National Institute Neurological Disorders StrokeScientific/Research Contact Telephone: 301-496-9135 Email: adam.hartman@nih.gov Richard T. Benson National Institute Neurological Disorders StrokeScientific/Research Contact Telephone: 301-827-9071 Email: richard.benson@nih.gov Chief Grants Management Officer National Institute Neurological Disorders StrokeFinancial/Grants Management Contact Email: ChiefGrantsManagementOfficer@ninds.nih.gov Sung Sug Sarah) Yoon National Institute Nursing Research Telephone: 301-402-6959 Email: sungsug.yoon@nih.gov Hua-Chuan Sim National Library Medicine Telephone: 301-594-4882 Email:   simh@mail.nlm.nih.gov Erica Spotts Office Behavioral Social Sciences Research Telephone: 301-594-2105 Email: spottse@mail.nih.gov Courtney Coombes Office the Director Telephone: 301-827-2408 Email: courtney.coombes@nih.gov Elizabeth Neilson Office Disease Prevention Telephone: 301-827-5578 Email: neilsone@mail.nih.gov Dave Thomas Office Research Women’s Health Telephone: 301-435-1313 Email: david.thomas@nih.gov Deidra Roach, M.D. National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-443-5820 Email: droach@mail.nih.gov

Notice Special Interest NOSI): Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System Notice Number: NOT-NS-20-051 Key Dates Release Date: April 30, 2020 First Available Due Date: 01, 2020 Expiration Date: April 15, 2021 Related Announcements NOT-NS-20-074 Notice Change Eligible Activity Codes NOT-NS-20-051 PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) NOT-OD-20-026 New NIH FORMS-F" Grant Application Forms Instructions Coming Due Dates or after 25, 2020 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Alcohol Abuse Alcoholism NIAAA) - New participating organization of 05/08/2020 due dates on/after 05/08/2020 Purpose NINDS issuing Notice Special Interest NOSI) highlight urgent need research Coronavirus Disease 2019 COVID-19) on biological effects the nervous system its causative agent, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2). Research interest must fall within NINDS’s scientific mission, is support basic, translational, clinical neuroscience research expand fundamental knowledge the brain nervous system to that knowledge reduce burden neurological disease. Research Objectives order rapidly improve our understanding the neurological consequences infection SARS-CoV-2 of COVID-19, NINDS encouraging submission applications supplements address biology, pathophysiology, prevention, diagnosis, sequelae, treatment the 2019 Novel Coronovirus are directly related the NINDS mission. National Institute Alcohol Abuse Alcoholism NIAAA) accept supplements NIAAA-supported projects fall within scope the NOT-NS-20-051 are relevant the mission the NIAAA. Specifically, NIAAA interested studies integrate alcohol exposure research topics outlined the announcement better understand, prevent, mitigate of neurobiological consequences SARS-CoV-2 infection COVID-19 individuals have Alcohol Disorders AUD). NIAAA encourages supplements be collaborative nature include appropriate neurological expertise the proposed projects. Application Submission Information Applications this initiative must submitted using of following opportunity announcements the subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) Applications research fall within scope an existing NINDS award should submitted through PA-18-591 (Parent Admin Supp Clinical Trial Optional). Eligible activity codes fare limited the mechanisms listed in PA-18-591. Applications research involve change the original scope an active award, still falls within mission the NINDS must apply through PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional). Eligible activity codes applications to PA-18-935 are limited the following mechanisms: P01, P50, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U19, U24, U44, U54, UG3, UH3). Scope defined the original specific aims, objectives, purposes a grant, methodology, approach, analyses other activities, the tools, technologies, timeframes needed meet grant's objectives. Changes include shifting research emphasis one disease area another, changing any aspects research involving vertebrate animals human subjects. you unsure whether application involve change scope, contact NINDS program director. instructions the SF424 R&R) Application Guide and PA-18-591 or PA-18-935 must followed, the following additions: funding consideration, applicants must include “NOT-NS-20-051"(without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. project period the supplement must exceed year. Application budgets not exceed 200,000 direct costs. Exceptions this budget limit be only NINDS pre-approval will only approved under very rare circumstances where work immediately impact public health. Research Strategy section the application limited 6 pages parent award must active the supplement application submitted e.g. within originally reviewed approved project period), regardless the time remaining the current project. Grants multi-year funding RF1) have additional constraints. Applicants these grants should contact program official determine eligibility. applications including those multi-project activity codes) must submitted electronically using single-project application form package Administrative supplement applications to PA-18-591 must the application form package the Competition ID contains FORMS-E-ADMINSUPP”. FOA be reissued application form packages containing FORMS-F-ADMINSUPP” May 25, 2020. Submissions to PA-18-591 must completed June 25, 2020 see NOT-OD-20-026 for details.) Submissions the reissued FOA be accepted or after 25, 2020 through expiration date this Notice. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Competitive revision applications to PA-18-935 must the application form package the Competition ID NOT-NS-20-051-FORMS-E." FOA be reissued a NOT-NS-20-051-FORMS-F” package May 25, 2020. Submissions to PA-18-935 must completed June 25, 2020. Submissions the reissued FOA be accepted or after 25, 2020 through expiration date this Notice. Applications be accepted a rolling basis from April 15, 2020 April 14, 2021 5:00 PM local time of applicant organization. NOSI expires on April 15, 2021. application submitted response this NOSI is received after expiration date be withdrawn Applications must specifically address issues potential biohazards, all research must conducted compliance the health safety requirements found the NIH Grants Policy Statement. Applications are responsive the terms this Notice not considered. Investigators planning apply response this NOSI strongly encouraged contact discuss proposed research/aims the Program Official the Parent Award advance better determine appropriateness interest the NINDS.   Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: Scientific/Research Contact(s) Please contact program officer your active award. NIAAA grantees, please direct inquiries Dr. Changhai Cui changhai.cui@nih.gov).

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.